Eighteen-month ADT Plus RT Recommended Standard for Patients With High-risk Prostate Cancer

Share this content:
Reducing the duration of androgen-deprivation therapy with radiation therapy from 36 months to 18 months is safe for patients with high-risk prostate cancer.
Reducing the duration of androgen-deprivation therapy with radiation therapy from 36 months to 18 months is safe for patients with high-risk prostate cancer.
The following article features coverage from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Click here to read more of Cancer Therapy Advisor's conference coverage.

Reducing the duration of androgen-deprivation therapy (ADT) with radiation therapy (RT) from 36 months to 18 months is safe and may represent a new standard of care for patients with high-risk prostate cancer (HRPC), according to data presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.1

The phase 3 study (ClinicalTrials.gov Identifier: NCT00223171) compared 3 years of ADT given with pelvic and prostate irradiation with 18 months of a similar treatment strategy. Three-year ADT plus RT was considered the standard care for men with HRPC (T3 to T4 disease, PSA greater than 7 ng/mL, Gleason score greater than 7).

Of the 630 men enrolled, 310 received 36 months of therapy and 320 men received 18 months of therapy.

Baseline demographics and disease characteristics were similar across the 2 arms of the study.

After a median follow up of 9.4 years, 10-year OS was 62.4% for men receiving 36 months of ADT therapy and 62.0% for men receiving 18 months of therapy. With a hazard ratio of 1.024, the difference was not significant (P = .8411).

A quality of life (QoL) analysis showed significant difference for men receiving 18 months of ADT therapy vs 36 months.

The authors concluded that “in HRPC, ADT combined with RT can be safely reduced from 36 to 18 months without compromising outcomes or QoL. 18 months of ADT represents a new standard of care in HRPC.”

RELATED: aBSI Is of Prognostic Significance in Castration-resistant Prostate Cancer

Read more of Cancer Therapy Advisor's coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting by visiting the conference page.

Reference

  1. Nabid A, Garant MP, Martin AG, et al. Duration of androgen deprivation therapy in high risk prostate cancer: Final results of a randomized phase III trial. J Clin Oncol. 2017;35(suppl; abstr 5008).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters